High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer

Gynecologic Oncology

Volumn 126, Issue 1, 2012, Pages 109-117

  Chen, Jie ^a   Xi, Bo ^a   Zhao, Yueran ^a   Yu, Yang ^b   Zhang, Jie ^a   Wang, Chunyu ^c  

^a SHANDONG UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c University of Houston   (United States)

Author keywords

HMGB1; Invasion; Migration; Ovarian cancer; Proliferation

Indexed keywords

COMPLEMENTARY DNA; CYCLIN D1; GELATINASE A; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DETERMINATION; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE SECTION;

ADENOCARCINOMA; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NIH 3T3 CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862757453     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.03.051     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hocke C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000;78:21-7. (Pubitemid 30439473)
3. Cho KR, Shih Ie M. Ovarian cancer. Annu Rev Pathol 2009;4:287-313.
4. Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415-28.
5. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559-64.
6. Bernues J, Espel E, Querol E. Identification of the core-histone-binding domains of HMG1 and HMG2. Biochim Biophys Acta 1986;866:242-51. (Pubitemid 16068022)
7. Wen L, Huang JK, Johnson BH, Reeck GR. A human placental cDNA clone that encodes nonhistone chromosomal protein HMG-1. Nucleic Acids Res 1989;17:1197-214. (Pubitemid 19062897)
8. Ge H, Roeder RG. The high mobility group protein HMG1 can reversibly inhibit class II gene transcription by interaction with the TATA-binding protein. J Biol Chem 1994;269:17136-40. (Pubitemid 24204034)
9. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010;28:367-88.
10. Leclerc E, Sturchler E, Vetter SW, Heizmann CW. Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease. Rev Neurosci 2009;20:95-110.
11. Ostberg T, Kawane K, Nagata S, Yang H, Chavan S, Klevenvall L, et al. Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. Arthritis Rheum 2010;62:2963-72.
12. Park S, Yoon SJ, Tae HJ, Shim CY. RAGE and cardiovascular disease. Front Biosci 2011;16:486-97.
13. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010;1799:149-56.
14. Evankovich J, Cho SW, Zhang R, Cardinal J, Dhupar R, Zhang L, et al. High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem 2010;285:39888-97.
15. Tang D, Kang R, Cao L, Zhang G, Yu Y, Xiao W, et al. A pilot study to detect high mobility group box 1 and heat shock protein 72 in cerebrospinal fluid of pediatric patients with meningitis. Crit Care Med 2008;36:291-5.
16. Huang W, Tang Y, Li L. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 2010;51:119-26.
17. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007;13:2836-48. (Pubitemid 46850704)
18. Tang D, Kang R, Zeh III HJ, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010;1799:131-40.
19. Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008;20:518-23.
20. Chen J, Zhang J, Zhao Y, Li J, Fu M. Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones. J Cancer Res Clin Oncol 2009;135:909-17.
21. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45. (Pubitemid 17082655)
22. Yang L, Yu Y, Kang R, Yang M, Xie M, Wang Z, et al. Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells. Leuk Lymphoma 2012;53:315-22.
23. TafaniM, Schito L, Pellegrini L, Villanova L,MarfeG, Anwar T, et al.Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation ofNF-{kappa}B. Carcinogenesis 2011;32:1167-75.
24. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, et al. Release of highmobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005;174:7506-15. (Pubitemid 40806253)
25. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60. (Pubitemid 30337069)
26. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-8. (Pubitemid 47463671)
27. Liu PL, Tsai JR, Hwang JJ, Chou SH, Cheng YJ, Lin FY, et al. High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol 2010;43:530-8.
28. Song B, Song WG, Li ZJ, Xu ZF, Wang XW, Wang CX, et al. Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells. Cell Biochem Funct 2012;30:11-7.
29. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003;17:1295-7.
30. Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010;136:677-84.
31. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005;64:92-100. (Pubitemid 40734743)
32. Akaike H, Kono K, Sugai H, Takahashi A, Mimura K, Kawaguchi Y, et al. Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 2007;27:449-57.
33. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009;7:38.
34. Bao G,QiaoQ, ZhaoH, He X. Prognostic value ofHMGB1 overexpression in resectable gastric adenocarcinomas.World J Surg Oncol 2010;8:52.
35. Shang GH, Jia CQ, Tian H, Xiao W, Li Y, Wang AH, et al. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med 2009;103:1949-53.
36. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008;216:167-75.
37. Shen X, Hong L, Sun H, Shi M, Song Y. The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep 2009;22:535-9.
38. Bassi R, Giussani P, Anelli V, Colleoni T, Pedrazzi M, Patrone M, et al. HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J Neurooncol 2008;87:23-33.
39. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009;6:e10.
40. Krynetskaia N, Xie H, Vucetic S, Obradovic Z, Krynetskiy E. High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs. Mol Pharmacol 2008;73:260-9. (Pubitemid 350294217)
41. Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 2007;28:1957-67. (Pubitemid 350198338)